JW-100 is under clinical development by Jupiter Wellness and currently in Phase I for Herpes Labialis (Oral Herpes). According to GlobalData, Phase I drugs for Herpes Labialis (Oral Herpes) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JW-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

JW-100 overview

JW-100 (CaniDermRX) is under development for the treatment of atopic dermatitis (eczema) and herpes labialis (cold sores). The drug candidate is a fixed-dose combination of cannabidiol and aspartame. It is administered topically as a cream. Cannabidiol acts by targeting CB2 receptor and aspartame targets cyclooxygenase 2 (COX2).

Jupiter Wellness overview

Jupiter Wellness a company operates as a pharmaceutical company and the company manufactures products for physical and mental benefits. It is headquartered in Jupiter, Florida, the US.

For a complete picture of JW-100’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.